~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~
~ This New Study and Other Independent, Institution-Led Research Continues to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations ~
RESEARCH TRIANGLE PARK, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center to evaluate use of PEDMARK® (sodium thiosulfate injection) in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin.
PEDMARK® is currently approved for pediatric patients one month of age and older with localized, non-metastatic solid tumors, and is also recognized by the National Comprehensive Cancer Network with a 2A recommendation for use in adolescent and young adult patients.
Fennec recently announced the initiation of two other institution-led clinical studies:
- In March 2026, Fennec announced that Tampa General Hospital (TGH) Cancer Institute is initiating a study evaluating the real-world clinical utility of PEDMARK® in reducing the risk of ototoxicity in AYA and adult cancer patients receiving cisplatin-based treatment. Additional investigator-initiated studies supporting the use of PEDMARK® in additional tumor types and patient populations, including AYA cancer, have been submitted to Fennec and are currently under review.
- In December 2025, Fennec announced that City of Hope, a U.S. cancer research and treatment organization, is evaluating PEDMARK® for the prevention of cisplatin-induced ototoxicity (CIO) in adult men with stage II-III metastatic testicular germ cell tumors.
Additional investigator-initiated studies supporting the use of PEDMARK® have been submitted to Fennec and are currently under review.